3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
5
Leukemia, Lymphocytic, Chronic, B-Cell
3
Immunoblastic Lymphadenopathy
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large-Cell, Anaplastic
2
Hodgkin Disease
2
Sezary Syndrome
1
Recurrence
1
Neoplasms
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia
1
Bronchiolitis Obliterans Syndrome
1
Anemia, Aplastic
1
Interventions
pegaspargase
14
Etoposide
11
Dexamethasone
11
Gemcitabine
10
spartalizumab
6
Oxaliplatin
4
sintilimab
3
Radiotherapy
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Methotrexate
3
Asparaginase
3
tislelizumab
2
camrelizumab
2
Lenalidomide
2
Drug Therapy
2
Cyclophosphamide
2
Cisplatin
2
Busulfan
2
Azacitidine
2
toripalimab
1
tofacitinib
1
ruxolitinib
1
romidepsin
1
pembrolizumab
1
fludarabine phosphate
1
avelumab
1
apatinib
1
Thalidomide
1
Sensitivity and Specificity
1
Psychiatric Rehabilitation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Lymphoma, Extranodal NK-T-Cell
×
Alemtuzumab
×
Clear all
NCT00725231
2012-05-07
A-CHOP-14
University of Göttingen
Phase 3
Unknown
274 enrolled